Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published 2022-11-14 20:06
RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations 2021-12-06 20:01
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results 2021-11-30 22:30
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients 2021-11-15 20:00
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill 2021-11-08 20:00
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients 2021-10-04 21:24
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval 2021-09-13 19:00
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis 2021-09-07 19:00
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 2021-09-07 18:00
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights 2021-08-26 19:56
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant 2021-08-26 19:50
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's 2021-08-23 19:00
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib 2021-07-19 19:21
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study 2021-06-28 19:00
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 2021-06-21 19:00
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study 2021-06-07 19:00
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 2021-05-26 19:12
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue 2021-04-09 19:00
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland 2021-03-22 19:00
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. 2021-02-23 20:33
1 2